Coultreon Biopharma
Heverlee
About Coultreon Biopharma
Onco3R Therapeutics develops oncology research tools and discovery services aligned with the 3R principles of replacing, reducing, and refining animal use. Offerings center on in vitro tumor models for evaluating drug response, mechanism-of-action, and combination strategies. Capabilities include custom assay development, multiparametric readouts, and analytical reporting to guide stage-gate decisions. Services support biopharma and research teams seeking non-animal approaches for efficacy and safety hypotheses prior to in vivo studies. Engagement models include project scoping, study execution, and data delivery integrated with existing workflows.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $125.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2026)
- Website: onco3r.com
- Phone: +32 16 85 25 10
Industries & Categories
Analytics, Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/coultreon-biopharma-190479 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.